MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms

This policy (L39918) covers multi-gene non-NGS panel testing and limited single-gene testing for the diagnostic evaluation of BCR-ABL-negative myeloproliferative neoplasms when all specified criteria are met, including use of consensus diagnostic criteria, prior BCR-ABL assessment (unless only PV suspected), assay sensitivity (VAF ≥4%), appropriate gene content for the suspected MPN subtype, and adequate analytical/clinical validation and technical assessment. NGS testing for myeloid malignancies is covered under a separate LCD (L38047), panels lacking minimum necessary genes are not covered, and testing for MRD or test-of-cure is excluded.

"Coverage is provided for multi-gene non-next generation sequencing (non-NGS) panel testing for the diagnostic workup of BCR-ABL-negative myeloproliferative neoplasms (MPNs)."

Sign up to see full coverage criteria, indications, and limitations.